




The relative strengths and weaknesses of Keros Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 190% points. The greatest weakness of Keros Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 383%, being 168% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	588,893
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,450
Liabilities, Non-Current	16,883
Other Assets	22,756
Other Compr. Net Income	0
Other Expenses	300
Other Liabilities	0
Other Net Income	23,780
Other Revenues	3,550
Property and Equipment	4,237
Research and Development	173,629
Selling, General and Administrative Expense	40,754

Output Variable	Value in 1000 USD
Assets	615,886
Liabilities	44,333
Expenses	214,683
Revenues	3,550
Stockholders Equity	571,553
Net Income	-187,353
Comprehensive Net Income	-187,353
BaseVar	451,116
ECR before Limited Liability	321%
Economic Capital Ratio	383%